In clinical trials involving active RA patients, the initial evidence indicated that JAK/STAT SMIs appeared to be more consistently effective than SAP/MAPK SMIs [57,58], especially those developed to inhibit specific p38 kinase isoforms [59,60,61] for suppressing disease activity. This evidence concerns the gene SOAT1 and rheumatoid arthritis.